医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ClearSight Announces Sale of Parent Company, Sharklet Technologies

2017年05月22日 PM11:00
このエントリーをはてなブックマークに追加


 

AURORA, Colo.

ClearSight LLC is pleased to announce the acquisition of its parent company Sharklet Technologies, Inc., by Peaceful Union, an equity medical device firm in Hangzhou, China. ClearSight LLC was co-founded by Drs. Kevin Cuevas and Shravanthi Reddy to develop the next generation intraocular lens (IOL) implant.

“We believe that the biomimetic approach used by Sharklet Technologies will not only produce the most advanced IOL, but will most likely enhance the performance of a wide range of ophthalmic products,” said Dr. Khalid “Kal” Mentak, CEO of ClearSight, LLC.

For more information see: www.clearsightiol.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005319/en/

CONTACT

ClearSight
Shravanthi Reddy, COO
805-350-8216
sreddy@clearsightiol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film
  • U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
  • NINLARO® (ixazomib)维持治疗3期试验达到主要终点,显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义
  • 維持療法としてのニンラーロ(イキサゾミブ)を検討する第3相試験は主要評価項目を達成し、移植後の多発性骨髄腫患者で無増悪生存期間の統計的に有意な改善を実証
  • EUSA Pharma:NICE核准靶向癌症免疫治疗药物QARZIBA®▼ (dinutuximab beta)用于治疗高危神经母细胞瘤患儿